Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Elicio Therapeutics Inc (NQ: ELTX ) 5.180 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 5.180 Bid (Size) 3.500 (1) Ask (Size) 5.180 (3) Prev. Close 5.180 Today's Range 5.180 - 5.180 52wk Range 2.960 - 11.45 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? June 28, 2024 Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors. Via Benzinga Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering June 28, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Performance YTD -12.65% -12.65% 1 Month +37.04% +37.04% 3 Month -41.47% -41.47% 6 Month +17.73% +17.73% 1 Year -48.20% -48.20% More News Read More Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? June 28, 2024 Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday June 28, 2024 Via InvestorPlace First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P February 01, 2024 Via News Direct Elicio Therapeutics Announces Proposed Public Offering June 27, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P June 27, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors June 10, 2024 Via News Direct 12 Health Care Stocks Moving In Thursday's Intraday Session May 16, 2024 Via Benzinga ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024 May 15, 2024 Via InvestorPlace Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry April 11, 2024 Via News Direct 12 Health Care Stocks Moving In Friday's After-Market Session April 05, 2024 Via Benzinga Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform April 05, 2024 Via News Direct Topics Death Exposures Death ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023 April 02, 2024 Via InvestorPlace Benzinga's 2024 Virtual Healthcare: What's Next In Health? March 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session March 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session March 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session February 08, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session February 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session February 07, 2024 Via Benzinga Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy February 06, 2024 Via News Direct Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 05, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy February 05, 2024 Via Benzinga First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P January 31, 2024 Via Benzinga Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002 January 30, 2024 Via News Direct Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
